Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA

Van Cangh, Paul;De Nayer, Philippe;DeVischer, L;Sauvage, P.;Opsomer, Reinier-Jacques;et.al.
(1996) 91st Annual Meeting of the American-Urological-Association — Location: Orloando (Fl) (4.May.1996)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 340.04 KB
Request a copy

Details

Authors
  • Van Cangh, PaulUCLouvain
    Author
  • De Nayer, PhilippeUCLouvain
    Author
  • DeVischer, L
    Author
  • Sauvage, P.
    Author
  • Tombal, Bertrandorcid-logoUCLouvain
    Author
  • Wese, François-XavierUCLouvain
    Author
  • Opsomer, Reinier-Jacques
    Author
Show more
Abstract
Objectives. Improved discrimination between prostate cancer (PC) and benign prostatic hyperplasia (BPH) is clearly needed. Our aim in this study was to evaluate whether the free to total prostate-specific antigen (PSA) ratio would be useful in the gray zone of 1.8-10 ng/mL total PSA range. Methods. In a consecutive series of 435 clinic patients referred for prostate evaluation, 308 had a total PSA <10 ng/mL (92 had PC and 216 BPH). Free and total PSA were measured, and the free to total PSA ratio calculated. Results. Total PSA values were significantly different between the two groups. For the 200 patients with a total PSA <6 ng/mL, no significant difference in total PSA values were seen (P = 0.411), whereas free to total PSA ratios remained statistically different (P < 0.001). Receiver operating characteristic (ROC) curve analysis comparing the performances of total PSA over the ratio of free to total PSA showed a clear advantage for the ratio at all sensitivity levels. Conclusions. These data demonstrate that in a significant number (n = 508) of prostatic patients in the diagnostic gray zone of 1.8-10 ng/mL total PSA, the routine use of free to total PSA might be advantageous in discriminating between cancer and benign hyperplasia. This advantage remained for total PSA <4 ng/mL. Further study is warranted to confirm these findings in an unselected population. Copyright 1996 by Elsevier Science Inc.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Van Cangh, P., De Nayer, P., DeVischer, L., Sauvage, P., Tombal, B., Lorge, F., Wese, F.-X., & Opsomer, R.-J. (1996). Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA. Urology, 48(6A), 67-70. https://doi.org/10.1016/S0090-4295(96)00613-9 (Original work published 1996)